SCHEMBL10004066

SCHEMBL10004066

CCOC(=O)c1sc2cc(CC)c(NC(=O)c3ccccc3)cc2c1OCC(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ RAB9A P51151 3/20 0.48
▸ MAPT P10636 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ KMT2A Q03164 4/20 0.46
▸ LMNA P02545 4/20 0.46
▸ GAA P10253 1/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ NOD2 Q9HC29 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ BRAF P15056 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003277 0.92 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003549 0.91 HTT (0.42) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003532 0.88 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003265 0.85 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003172 0.82 HTT (0.43) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003771 0.81 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003431 0.80 HPGD (0.35) RAB9AMAPTHPGDNPC1KMT2A
SCHEMBL10002970 0.79 MAPT (0.39) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL10003405 0.78 SMO (0.52) SMN1; SMN2MAPTKMT2ALMNAPOLB
SCHEMBL10003575 0.78 MAPT (0.48) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885SMN1; SMN2 3164/4885RAB9A 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback